For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s.
Scope of the Report:
The threat of substitutes arises when there are similar products developed by competitors which satisfy the market needs. When consumers have access to substitute products which can satisfy their market needs, then manufacturers and suppliers lose their bargaining power. Consumers are able to purchase competitor's products if they are not satisfied with product price or quality. In order for suppliers to tackle the challenge of threat of substitutes, they have to innovate products which meet the needs of their target market segments.
The worldwide market for PEGylated Proteins is expected to grow at a CAGR of roughly 3.9% over the next five years, will reach 3910 million US$ in 2024, from 3230 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the PEGylated Proteins in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- ENZON Pharmaceuticals
- Merck Sharp & Dohme
- Roche
- Pfizer
- Amgen
- UCB
- Crealta (Savient)
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Colony Stimulating Factors
- Interferons
- Erythropoietin (EPO)
- Recombinant Factor Viii
- Monoclonal Antibodies
- Others
Market Segment by Applications, can be divided into
- Cancer Treatment
- Hepatitis
- Chronic Kidney Disease
- Leukemia
- SCID
- Rheumatoid Arthritis & Crohn's Disease
- Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PEGylated Proteins product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of PEGylated Proteins, with price, sales, revenue and global market share of PEGylated Proteins in 2017 and 2018.
Chapter 3, the PEGylated Proteins competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PEGylated Proteins breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, PEGylated Proteins market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe PEGylated Proteins sales channel, distributors, customers, research findings and conclusion, appendix and data source.